药物对CYP3A酶活性和蛋白质表达的作用通过Ubiquitination修改法规
Fang Wang1, Xiwei Gu1, Haiying Hong1
1Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Basic & clinical pharmacology & toxicology
|September 16, 2025
概括
药物代谢通过cytochrome P450 3A4 (CYP3A4) 在低氧状态下可能会受损. 缺氧加剧了药物诱导的CYP3A4抑制,可能增加毒性反应和药物相互作用.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 药物新陈代谢 药物新陈代谢
- 生物化学 生物化学
背景情况:
- 细胞染色体P450 3A4 (CYP3A4) 对于药物代谢至关重要,但其抑制存在药物诱导毒性的风险.
- 缺氧是一种病理状况,可能会影响药物代谢和CYP3A4活性.
研究的目的:
- 研究药物对CYP3A4酶活性和蛋白质表达的影响.
- 为了确定缺氧是否会加剧药物诱导的CYP3A4抑制.
- 阐明在低氧条件下CYP3A4调节的分子机制.
主要方法:
- 分子对接以预测药物-CYP3A4相互作用.
- 在体内研究使用Sprague Dawley大鼠在正常 (21% FiO2) 和缺氧 (10% FiO2) 条件下进行了14天.
- 在体外分析使用高性能液态染色学 (HPLC) 的肝脏显微体.
- 在体内测量血液中的药物度,使用LC-MS/MS.
- 免疫沉以研究泛化-蛋白酶途径和E3泛酸酶gp78.8.
主要成果:
- 分子对接表明CYP3A4活性区域内的药物结合部位,可能会影响药物代谢.
- 低氧加剧了药物诱导的CYP3A4抑制.
- 发现药物通过涉及E3泛素合酶gp78.8.的泛素-蛋白酶通路调解CYP3A4降解.
- 在低氧条件下,这些效应更为明显.
结论:
- 药物诱导的CYP3A4抑制可能会因缺氧而恶化.
- 这项研究提供了对低氧下CYP3A4调节的分子机制的见解,涉及gp78介导的泛化-蛋白酶体通路.
- 研究结果支持合理的临床药物治疗策略,以减轻低氧患者的药物相互作用和毒性.
相关概念视频
Pharmacokinetics: Drug–Drug Interactions
364
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
364
Regulation of Expression at Multiple Steps
1.3K
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
1.3K
Regulated Protein Degradation
8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K
Covalently Linked Protein Regulators
8.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Factors Affecting Drug Biotransformation: Biological
524
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
524


